Analysis of the Occurrence and Influencing Factors of Adverse Reactions in the Chemotherapy Regimens Containing Temozolomide
WANG Xiong1,2, DIAO Chang-dong1,2, ZHU Hai-xia1,2, YUAN Qi1,2, LIU Jin-mei1,2, LI Shi-jun1,2, ZHANG Yu1,2, SHI Chen1,2*
1. Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China; 2. Hubei Province Clinical Research Center for Precision Medicine for Critical Illness, Wuhan 430022, China
Abstract：OBJECTIVE To analyze the occurrence and influencing factors of adverse reactions in the chemotherapy regimens containing temozolomide and provide reference for rational clinical application. METHODS Patients who use chemotherapy regimen of temozolomide in Union Hospital of Tongji Medical College, Huazhong University of Science and Technology from January 2008 to December 2019 were identified. Socio-demographic data of patients and specific clinical adverse reactions were collected. Single factor chi-square test and multivariate logistic regression analysis were used to analyze the influencing factors of adverse reactions. RESULTS Of the 1 057 cases, 922 were included in the study, including 484 adverse reactions. Univariate analysis showed that radiotherapy, chemotherapy cycle, clinical stage, chemotherapy regimen were the influencing factors of adverse reactions (P<0.05). The results of multi-factor analysis showed that chemotherapy regimen, chemotherapy cycle and clinical stage were the influencing factors of overall adverse reactions (P<0.05). Chemotherapy regimen, chemotherapy cycle and clinical stage are the influencing factors of adverse reactions of blood system (P<0.05). Clinical diagnosis, gender, age and clinical stage are influencing factors for gastrointestinal adverse reactions (P<0.05). Clinical diagnosis, chemotherapy regimen, and age are influencing factors of liver function (P<0.05). CONCLUSION Adverse effects of chemotherapy regimens containing temozolomide are more common in clinical application, and the influencing factors in various systems are different. During clinical medication, patients with relevant influencing factors should be monitored in order to ensure the safety of the drugs.
汪雄, 刁长冬, 朱海霞, 袁琦, 刘金梅, 李石军, 张玉, 史琛. 含替莫唑胺化疗方案不良反应发生情况及影响因素分析[J]. 中国药学杂志, 2021, 56(17): 1414-1419.
WANG Xiong, DIAO Chang-dong, ZHU Hai-xia, YUAN Qi, LIU Jin-mei, LI Shi-jun, ZHANG Yu, SHI Chen. Analysis of the Occurrence and Influencing Factors of Adverse Reactions in the Chemotherapy Regimens Containing Temozolomide. Chinese Pharmaceutical Journal, 2021, 56(17): 1414-1419.
FRIEDMAN H S, KERBY T, CALVERT H. Temozolomide and treatment of malignant glioma[J]. Clin Cancer Res, 2000, 6(7):2585-2597.
[2]
BI X L, HUANG G H, ZHANG N, et al. Study on pharmacokinetics in rabbit and body distribution in mice of temozolomide solid lipid nanoparticles by intravenously injection[J]. Chin Pharm J(中国药学杂志), 2007,42(21):1655-1660.
[3]
GRIECO A, TAFURI M A, BIOLATO M, et al. Severe cholestatic hepatitis due to temozolomide:An adverse drug effect to keep in mind. Case report and review of literature[J]. Medicine (Baltimore), 2015, 94(12):e476.
[4]
HE J Y, HU C H. Research progress of temozolomide in the treatment of glioblastoma drug resistance mechanism[J]. Chin J Mod Appl Pharm(中国现代应用药学), 2019, 36(23): 3001-3007.
[5]
DU X L. A new drug for the treatment of refractory glioblastoma multiforme-temozolomide[J]. Chin Pharm J(中国药学杂志), 2000,35(2): 135-136.
[6]
STUPP R, MASON W P, VAN DEN BENT M J, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma[J]. N Engl J Med, 2005, 352(10):987-996.
[7]
BAI Y, CHEN Y, HONG X, et al. Newcastle disease virus enhances the growth-inhibiting and proapoptotic effects of temozolomide on glioblastoma cells in vitro and in vivo[J]. Sci Rep, 2018, 8(1):11470.
[8]
HU J, PAN J, LUO Z G, et al. Therapeutic effect analysis of postoperative IMRT combined with temozolomide chemotherapy[J]. China Med Her(中国医药导报), 2012, 9(21): 166-167.
[9]
ZHOU L, AN G Y, YUE Z D, et al. Clinical study of temozolomide combined with radiotherapy in brain metastasis of non-small cell lung cancer [J]. J China Pharm(中国药房), 2011, 22(22): 2072 -2074.
[10]
RICARDO J K, MARC L O, GAETAN M, et al. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma-A Critical Review[J]. Clin Med Oncol, 2008,2:421-422.
[11]
ZHAI X M, WANG J P, ZHANG J N, et al. Comparison of the efficacy of two concurrent radiochemotherapy regimens for postoperative adult brain malignant glioma[J]. J South Med Univ(南方医科大学学报), 2012, 32(2): 255-257.
[12]
DAI B L, QI N, LI J C, et al. Temozolomide combined with PD-1 Antibody therapy for mouse orthotopic glioma model[J]. Biochem Biophys Res Commun, 2018, 501(4):871-876.
[13]
ZHOU B Y, MAO Q, WANG P, et al. The adverse effects analysis of Temozolomide in glioma chemotherapy[J]. Chin J Neuro-Oncol(中国神经肿瘤杂志), 2012, 10(1): 14-18.
[14]
ARMSTRONG T S, CAO Y M, SCHEURER M E, et al. Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors.[J]. Neuro Oncol, 2009, 11(6):825-832.
2021, Vol. 56 
